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Abstract: OBJECTIVES Novel therapeutics are urgently required for the treatment of carbapenem-
resistant Acinetobacter baumannii (CRAB) causing critical infections with high mortality. Here we
assessed the therapeutic potential of the clinical-stage drug candidate EBL-1003 (crystalline free base
of apramycin) in the treatment of CRAB lung infections. METHODS The genotypic and phenotypic
susceptibility of CRAB clinical isolates to aminoglycosides and colistin was assessed by database mining
and broth microdilution. The therapeutic potential was assessed by target attainment simulations on
the basis of time-kill kinetics, a murine lung infection model, comparative pharmacokinetic analysis in
plasma, epithelial lining fluid (ELF) and lung tissue, and pharmacokinetic/pharmacodynamic (PKPD)
modelling. RESULTS Resistance gene annotations of 5451 CRAB genomes deposited in the National
Database of Antibiotic Resistant Organisms (NDARO) suggested >99.9% of genotypic susceptibility to
apramycin. Low susceptibility to standard-of-care aminoglycosides and high susceptibility to EBL-1003
were confirmed by antimicrobial susceptibility testing of 100 A. baumannii isolates. Time-kill experiments
and a mouse lung infection model with the extremely drug-resistant CRAB strain AR Bank 0282 resulted
in rapid 4-log CFU reduction both in vitro and in vivo. A single dose of 125 mg/kg EBL-1003 in CRAB-
infected mice resulted in an AUC of 339 h × ฀g/mL in plasma and 299 h × ฀g/mL in ELF, suggesting a
lung penetration of 88%. PKPD simulations suggested a previously predicted dose of 30 mg/kg in patients
(creatinine clearance (CLCr) = 80 mL/min) to result in >99% probability of -2 log target attainment for
MICs up to 16 ฀g/mL. CONCLUSIONS This study provides proof of concept for the efficacy of EBL-1003
in the treatment of CRAB lung infections. Broad in vitro coverage, rapid killing, potent in vivo efficacy,
and a high probability of target attainment render EBL-1003 a strong therapeutic candidate for a priority
pathogen for which treatment options are very limited.
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Objectives: Novel therapeutics are urgently required for the treatment of carbapenem-resistant Acine-
tobacter baumannii (CRAB) causing critical infections with high mortality. Here we assessed the thera-
peutic potential of the clinical-stage drug candidate EBL-1003 (crystalline free base of apramycin) in the
treatment of CRAB lung infections.
Methods: The genotypic and phenotypic susceptibility of CRAB clinical isolates to aminoglycosides and
colistin was assessed by database mining and broth microdilution. The therapeutic potential was
assessed by target attainment simulations on the basis of timeekill kinetics, a murine lung infection
model, comparative pharmacokinetic analysis in plasma, epithelial lining fluid (ELF) and lung tissue, and
pharmacokinetic/pharmacodynamic (PKPD) modelling.
Results: Resistance gene annotations of 5451 CRAB genomes deposited in the National Database of
Antibiotic Resistant Organisms (NDARO) suggested >99.9% of genotypic susceptibility to apramycin. Low
susceptibility to standard-of-care aminoglycosides and high susceptibility to EBL-1003 were confirmed
by antimicrobial susceptibility testing of 100 A. baumannii isolates. Timeekill experiments and a mouse
lung infection model with the extremely drug-resistant CRAB strain AR Bank #0282 resulted in rapid 4-
log CFU reduction both in vitro and in vivo. A single dose of 125 mg/kg EBL-1003 in CRAB-infected mice
resulted in an AUC of 339 h  mg/mL in plasma and 299 h  mg/mL in ELF, suggesting a lung penetration
of 88%. PKPD simulations suggested a previously predicted dose of 30 mg/kg in patients (creatinine
clearance (CLCr) ¼ 80 mL/min) to result in >99% probability of e2 log target attainment for MICs up to 16
mg/mL.
Conclusions: This study provides proof of concept for the efficacy of EBL-1003 in the treatment of CRAB
lung infections. Broad in vitro coverage, rapid killing, potent in vivo efficacy, and a high probability of
target attainment render EBL-1003 a strong therapeutic candidate for a priority pathogen for which
treatment options are very limited. Katja Becker, Clin Microbiol Infect 2020;▪:1
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Introduction
Carbapenem-resistant Acinetobacter baumannii (CRAB) strains
are characterized by nosocomial transmission, high-level drug
resistance, and high mortality. CRAB has consistently been ranked
at the top of both the World Health Organization's (WHO's) list of
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critical priority pathogens and the US Centers for Disease Control
and Prevention's (CDC's) most urgent health threats [1,2]. CRAB
strains are primarily of concern in ventilator-associated bacterial
pneumonia (VABP) and bloodstream infections (BSIs) in critical ill
patients, and treatment options often rely on combination therapy
that includes a last-resort drug, often colistin [3,4]. Drug resistance
is prevalent among clinical A. baumannii isolates, and the propor-
tion of CRAB strains has reached a concerning level of up to 90% in
some parts of the world [5].
Aminoglycosides used to play an important role in treatment of
CRAB, representing a common constituent in drug combination
therapy. However, the use of standard-of-care aminoglycosides
such as amikacin is frequently compromised by increasing levels of
drug resistance [6]. Various mechanisms confer resistance to ami-
noglycoside in A. baumannii, including 16S ribosomal RNA meth-
yltransferases (RMTases) or aminoglycoside-modifying enzymes
(AMEs) such as N-acetyltransferases (AACs), O-phospho-
transferases (APHs), and O-nucleotidyltransferases (ANTs) [7,8].
RMTase-mediated pan-aminoglycoside resistance has been
observed with particularly high prevalence in CRAB and other
carbapenem-resistant Gram-negative isolates, stressing the serious
threat of antimicrobial resistance and the pressing need for new
treatment options [9,10].
EBL-1003, a crystalline free base of apramycin, is a candidate
drug currently in clinical development with support from the
Innovative Medicines Initiative's European Gram-Negative Anti-
bacterial Engine (IMI ENABLE) [11]. Based on its unique chemical
structure, comprising an unusual bicyclic octose moiety, apramycin
evades almost all clinically relevant AMEs and is also unaffected by
RMTase-mediated pan-aminoglycoside resistance [12]. Modifica-
tion by the N-acetyltransferase AAC(3)-IV remains the sole clini-
cally relevant resistance mechanism for apramycin [12,13]. Several
research groups have independently reported outstanding in vitro
activity of apramycin against highly drug-resistant clinical isolates
of A. baumannii [12,14,15].
Based on these encouraging reports on apramycin activity, we
sought proof of concept for the therapeutic efficacy of EBL-1003 in
pulmonary infections, and insights into lung penetration and
therefore the probability of target attainment (PTA) in respiratory
CRAB infection.
Methods
We analysed the resistance gene annotations of CRAB isolates
deposited in the National Database of Antibiotic Resistant Organ-
isms (NDARO) and subsequently assessed the activity of EBL-1003
against a panel of clinical A. baumannii isolates. The efficacy of
EBL-1003 against CRAB was further investigated in a murine lung
infection model. We used matrix-assisted laser desorption/ioniza-
tion mass spectrometry imaging (MALDI-MSI) to visualize drug
distribution in the lung. Lastly, we studied the pharmacokinetics
and pharmacodynamics (PKPD) to assess the PTA in epithelial lin-
ing fluid (ELF). Full details of all methods are provided in the web-
only Supplementary Material.
Results
Genotypic analysis of CRAB clinical isolates
First, we wanted to understand the prevalence of aminoglyco-
side resistance in a large panel of CRAB isolates. Towards this end
we analysed the resistance gene annotations of 5707 clinical
A. baumannii isolates deposited in the National Database of Anti-
biotic Resistant Organisms (NDARO) and classified 5451 isolates
(95.5%) as carbapenem-resistant (CRAB) based on carbapenemase
annotations in those genomes; 4305 (78.0%) of these CRAB ge-
nomes contained at least one aminoglycoside resistance gene. The
most prevalent aminoglycoside resistance genes were aph(30)-I,
annotating to 2275 (41.7%) CRAB genomes, followed closely by the
RMTase armA (2164; 39.7%) and the AMEs aac(60)-I (1507; 27.7%),
aph(30)-VI (1366; 25.1%), and aac(3)-I (1002; 18.4%) (Fig.1A); aac(3)-
IV was the least prevalent aminoglycoside resistance gene and
annotated to only one (0.02%) of the 5451 CRAB genomes. The only
colistin resistance gene in the CRAB isolates wasmcr-4 found in two
genome annotations (0.04%).
From the annotation of aminoglycoside resistance genes, we
inferred an aminoglycoside resistome for each isolate that we trans-
lated into genotypic resistance to individual aminoglycosides, and the
lack of any resistance gene into genotypic susceptibility (Fig. 1B,
Supplementary Material Table S1). This allowed us to compare the
genotypic susceptibility to apramycin in deposited NDARO isolates
with that to other aminoglycosides and colistin. Genotypic suscepti-
bility of CRAB isolates to apramycin and to colistin was >99.9%. The
genotypic susceptibility to standard-of-care aminoglycosides was
considerably lower than for apramycin or colistin.
Antimicrobial susceptibility of CRAB clinical isolates
Next, we determined the in vitro activity of EBL-1003 in com-
parison to standard-of-care drugs in a panel of 100 geographically
and phenotypically diverse A. baumannii isolates, of which 86 were
identified as CRAB (meropenem MIC 4 mg/mL). In the overall
panel, 99 A. baumannii isolates were susceptible to EBL-1003
(applying an apramycin epidemiological cut-off value (ECOFF) of
16 mg/mL [12]), and the MIC90 for EBL-1003 was 8 mg/mL. The MIC90
of amikacin, tobramycin, gentamicin and plazomicin was >128 mg/
mL. Of the 86 CRAB isolates, 85 were apramycin susceptible and 79
showed susceptibility to colistin (MIC <2 mg/mL) while all other
tested drugs failed to provide sufficient coverage of the CRAB iso-
lates in the panel (Fig. 2). All of the 68 A. baumannii isolates with a
pan-aminoglycoside-resistant phenotype had an apramycin MIC of
16 mg/mL. Notably, 63 A. baumannii isolates and 57 CRAB isolates
(66.3%) were of confirmed respiratory origin.
The in vitro activity of EBL-1003 against CRAB led us to further
explore the bactericidal activity in timeekill experiments. For
subsequent analyses we selected the XDR strain A. baumannii AR
Bank #0282, which is characterized by OXA-23- and OXA-66-
mediated carbapenem resistance [16]. The MIC of EBL-1003 was
determined as 4 mg/mL for this strain (Supplementary Material
Table S2). Concentrations as low as 3 mg/mL (0.75-fold MIC) resul-
ted in CFU reductions, and concentrations of 16 mg/mL (4-fold
MIC; ¼ of Cmax observed in mice after a single administration of
20 mg/kg) irrevocably suppressed regrowth of persister pheno-
types (Supplementary Material Fig. S1).
Lung efficacy dose fractionation studies, lung PK, and MALDI-MS
imaging
We then tested the efficacy of EBL-1003 in a murine
A. baumannii lung infection model with the strain AR Bank #0282.
All mice survived the predefined study period of 26 h post infec-
tion. A subcutaneous dose of 5 mg/kg EBL-1003 at q6h (total daily
dose of 20 mg/kg) resulted in a >2-log10 (>99%) reduction in CFU
counts in lung tissue at 24 h when compared with the start of
treatment. Doses of >5 mg/kg at q6h resulted in a >4-log10
(>99.99%) reduction in bacterial burden (Fig. 3A, Supplementary
Material Fig. S2).
The pharmacokinetics and lung penetration of EBL-1003 were
assessed in the same lung infection model as the efficacy. For a
single dose of 20 mg/kg, the Cmax in plasma was 67 mg/mL at
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Tmax ¼ 0.167 h. Overall, the Cmax of EBL-1003 in the ELF was lower
than in plasma, but the AUC in ELF resembled the AUC in plasma
(Fig. 3B,C). Hence, EBL-1003 penetrated into the lung efficiently and
reached an AUC0e24,ELF/AUC0e24,plasma ratio of 0.88 at a dose of 125
mg/kg. The AUCplasma of 339 h mg/mL for this dose inmice roughly
corresponds to the expected therapeutic AUC in humans (Fig. 3B).
The human dose predicted to achieve a similar AUCplasma exposure
level is approximately 30 mg/kg [17].
Tissue distribution of EBL-1003 in the lungs was further studied
by MALDI-MSI after subcutaneous administration in healthy mice.
Wewere thus able to visualize the penetration of EBL-1003 into the
lung tissue. TheMS images indicated that EBL-1003was distributed
evenly across the entire lung, and confirmed peak tissue concen-
tration at about one hour post administration. Drug clearance over
time in lung tissue was were in agreement with decreasing drug
concentration in ELF (Fig. 3D).
Fig. 1. Prevalence of aminoglycoside- and colistin-resistance genes and inferred genotypic susceptibility of 5451 carbapenem-resistant Acinetobacter baumannii (CRAB) isolates. (A)
Aminoglycoside resistance gene annotations for 5451 CRAB genomes deposited in the National Database of Antibiotic Resistant Organisms (NDARO) as of 1st September 2020. (B)
The resulting genotypic susceptibility of CRAB isolates to apramycin (APR) in comparison to plazomicin (PLZ), arbekacin (ARB), tobramycin (TOB), amikacin (AMI), gentamicin (GEN),
and colistin (COL).
Fig. 2. Minimal inhibitory concentration (MIC) distributions for 100 clinical Acinetobacter baumannii isolates: carbapenem-resistant (CRAB) n ¼ 86; carbapenem-susceptible
A. baumannii (CSAB) n ¼ 14.
K. Becker et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 3
Please cite this article as: Becker K et al., Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice, Clinical
Microbiology and Infection, https://doi.org/10.1016/j.cmi.2020.12.004
PKPD and probability of target attainment (PTA) analysis
Next, we integrated plasma and ELF data with the results of the
efficacy study (pharmacodynamic, PD) to study which PK/PD index
reveals the best correlation. PK/PD indices based on plasma and ELF
concentrations had similar correlations. The two indices fAUCELF/
MIC and fCmax,ELF/MIC showed good correlation with R
2 values of
0.82 and 0.87, respectively, whereas fT/MIC showed lower R2 values
of 0.59e0.66. The AUC and the Cmax were therefore much better
predictors of CFU reduction in lung than the time overMIC. fAUCELF/
MIC target values for stasis, 1-log10 and 2-log10 CFU reduction in
lung tissue at 24 h compared to start of treatment were 6.31, 7.26
and 8.34 (Fig. 4A,B).
Lastly, we simulated the PTA in humans based on a predicted
human dose of 30 mg/kg, a clearance rate of 120 and 80 mL/min,
and the assumption of 88% lung penetration. For all effect targets in
adult healthy males with a clearance of 120 mL/min, the PTA was
>99.9% for MICs 8 mg/mL. For an MIC of 16 mg/mL, the PTA
remained >95% for stasis and 1-log10 CFU reduction but dropped to
90.1% for 2-log10 CFU reduction. For a hypothetical MIC of 32 mg/
mL, the PTA dropped below 50% for all effect targets. In adult males
with reduced renal function (creatinine clearance (CLCr) 80 mL/
min), higher PTA was predicted due to a higher drug exposure by
the same dose. In these patients, the PTA was >99% for all effect
targets up to anMIC of 16 mg/mL. The PTA dropped below 85% for all
effect targets for an MIC 32 mg/mL (Fig. 4 C,D). PTA results were
only slightly affected for dose variations between 20 and 35 mg/kg
(Supplementary Material Fig. S3).
Discussion
The findings in this study provide the first proof of concept for
lung penetration and the efficacy of apramycin in lung infections in
mice. Results were assessed in a PKPD evaluation that supports
target attainment in ELF for the predicted therapeutic dose of EBL-
1003 in humans. The study further confirms and extends on pre-
vious reports of the superior in vitro activity of apramycin against
A. baumannii clinical isolates by analysing the relevant resistance
gene annotations in an unprecedented high number of 5451 CRAB
genomes.
In CRAB genomes deposited in NDARO, we screened for gene
annotations and inferred a resistance phenotype based on this
genotypic informationwhich allowed us to assess a large number of
isolates. However, in this screening, unspecific resistance mediated
by drug efflux and potential gradual effects on susceptibility (in-
termediate versus resistant) could not be considered, and thus
genotypic assessment might not in all cases fully reflect the
phenotype. Based on AMEs and RMTases as the major amino-
glycoside resistance mechanisms in CRAB, we inferred a very high
genotypic susceptibility from the low prevalence of apramycin and
colistin resistance genes in CRAB. Colistin is a last-resort drug often
used in therapeutic regimens for CRAB infection, but is only used in
patients with limited treatment options because of the very high
nephrotoxicity of this drug [3,18,19]. Our database analysis sug-
gested high susceptibility to apramycin, rendering EBL-1003 an
alternative candidate drug with a coverage of CRAB isolates that
compares well with that of colistin. Our data also provide a
Fig. 3. Mouse lung efficacy and pharmacokinetics of EBL-1003 (apramycin). (A) Efficacy against XDR carbapenem-resistant Acinetobacter baumannii (CRAB) strain AR Bank #0282 in
a murine lung infection model. Doses were administered q6h and the cumulative daily dose is depicted. Composite results of two dose-fractionation studies are shownwith colony-
forming unit (CFU) reductions calculated against the study-specific baseline (mean ± SD). (B) Concentration of EBL-1003 in the epithelial lining fluid (ELF) and plasma of CRAB-
infected mice after a single subcutaneous dose of 125 mg/kg (mean ± SD; LOQ ¼ 0.01). This dose resulted in an AUC0e24,plasma of 339 h  mg/mL and an AUC0e24,ELF of
299 h  mg/mL (lung penetration ratio ¼ 0.88). (C) The AUC0e∞ in ELF and plasma after single subcutaneous doses of 20, 50, 125 and 400 mg/kg. (D) Distribution of EBL-1003 in lung
tissue after a single subcutaneous dose of 400 mg/kg in healthy mice. Tissue sections were analysed by matrix-assisted laser desorption/ionization mass spectrometry imaging
(MALDI-MSI) quantifying EBL-1003 relative to kanamycin as internal standard. Ion distribution images of m/z 578.24 (potassiated EBL-1003) at (I) 1 h, (II) 2 h, (III) 4 h post
administration, and (IV) in control tissue. Ion intensities are shown using a rainbow scale with maximum intensity scaled to 3%. Scale bar 1 mm; lateral resolution 100 mm.
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rationale for limited clinical utility of other aminoglycoside anti-
biotics in CRAB infections, providing further support for the specific
differentiation of EBL-1003 within its own drug class.
Both EBL-1003 and colistin also showed very good in vitro
coverage of 100 clinical A. baumannii isolates, the majority of which
were CRAB and/or pan-aminoglycoside-resistant. Timeekill ex-
periments confirmed rapid multi-log bactericidal activity of EBL-
1003 against the XDR A. baumannii isolate AR Bank #0282.
Phenotypic assessments in the present and in previous studies are
in agreement with the genotypic resistance profiling of the CRAB
genomes deposited in the NDARO, indicating that EBL-1003 and
colistin are the only two effective antibiotics in the panel tested
against CRAB. Although a relatively small number of isolates was
assessed in vitro in comparison to the genotypic analysis, the results
are generally in agreement with previous studies on the
susceptibility of A. baumannii and other Gram-negatives to apra-
mycin [12,15,20,21]. Genetic information was unavailable for the
isolates tested in this study, but it is reasonable to assume that the
single clinical isolate resistant to EBL-1003 carries the aac(3)-IV
resistance gene, which has been described as the only apramycin
resistance mechanism of clinical relevance [12,13]. Notably, a sig-
nificant proportion of the clinical isolates included in our in vitro
assays were of respiratory origin, and respiratory CRAB infections
have been reported as one of the largest hospital burdens, with
colistin often left as the only effective treatment option currently
available on the market [18,22].
The in vivo efficacy of apramycin has previously been demon-
strated by James Kirby and colleagues in a murine thigh infection
model [23]. To our best knowledge, this was the first and thus far
the only proof of concept for the remarkable efficacy of apramycin
Fig. 4. Pharmacokinetic/pharmacodynamic (PK/PD) analysis of EBL-1003 (apramycin) in plasma and epithelial lining fluid (ELF). (A) Plasma and (B) ELF PK/PD index correlation for
Acinetobacter baumannii strain AR Bank #0282 with an MIC of 4 mg/mL. For the fAUC/MIC and fCmax/MIC graphs, PK/PD index value for the drug-free vehicle (which should be 0) was
set to 0.1 to enable semi-logarithmic plotting. (C) Probability of target attainment (PTA) in the lung for stasis, 1- and 2-log10 kill based on 1000 simulations of EBL-1003 admin-
istration at a dose of 30 mg/kg as 30-minute intravenous infusion to an adult healthy male, creatinine clearance (CLCr) ¼ 120 mL/min, and (D) to an adult male with reduced renal
function, CLCr ¼ 80 mL/min.
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against A. baumannii. The outstanding in vitro activity of EBL-1003
in our murine A. baumannii lung infection model supports the
notion of apramycin as a potent alternative to colistin in the
treatment of respiratory CRAB infections, and provides proof of
concept for the efficacy in lung infections as well. As was expected,
based on the in vitro timeekill analysis, apramycin led to highly
potent killing of A. baumannii AR Bank #0282 with low fAUC/MIC
targets in both ELF and plasma.
The excellent efficacy of EBL-1003 in the lungs of infected mice
indicated sufficient penetration into lung tissue and ELF. Indeed,
our pharmacokinetic studies revealed a high AUC in ELF resembling
the AUC in plasma, suggesting a lung penetration of 88% at a dose
predicted to result in human therapeutic plasma exposure. MS
imaging suggested even tissue distribution of the candidate drug.
The human AUC lung penetration ratio of aminoglycosides has been
reported to range from a low 13% for plazomicin to a high 77% for
gentamicin [24e26]. High lung penetration and efficacy of EBL-
1003 in mice warrants further clinical assessment of EBL-1003 to
demonstrate sufficient drug penetration into human ELF after
parenteral administration in humans.
In our model, the EBL-1003 exposure in plasma and ELF
(fAUCplasma and fAUCELF, respectively) achieved by doses corre-
sponding to the predicted therapeutic dose for systemic Escherichia
coli infections in humans (30mg/kg) were considerably higher than
the predicted target values for A. baumannii [17]. PK/PD predictions
suggested >99.9% PTA for MIC 8 mg/mL in the lungs of healthy
individuals and even higher PTA in patients with a reduced (80 mL/
min) creatinine clearance, representative of typical patients in the
target patient population [27,28]. In the absence of a model for the
human PK of EBL-1003, human concentration time profiles were
simulated from amodel of human PK of gentamicin.While being an
assumption, this hypothesis is backed up by the chemical similarity
of the twomolecules and the similarity of their PK in various animal
species [17].
The present study emphasizes the great potential of EBL-1003 in
the treatment of A. baumannii infections based on its unprece-
dented coverage of multidrug-, carbapenem- and aminoglycoside-
resistant isolates, its efficient lung penetration, and its promising
PTA. Intrinsically lower toxicity of EBL-1003 has been proposed to
provide for an improved safety margin when compared to colistin
or other aminoglycosides antibiotics [29,30].
The WHO has not only prioritized CRAB infections as the most
critical medical need in antibacterial therapy, as indicated above.
It has also monitored the clinical development activities in the
field to find a critical gap between the prioritized pathogens and
the current clinical pipeline [11]. The current pipeline is domi-
nated by b-lactam/b-lactamase inhibitor combinations, which
have in part been successful in addressing critical infections with
carbapenem-resistant Enterobacterales (CRE), but have demon-
strated little benefit in treating P. aeruginosa and A. baumannii. Of
the 52 antibiotics listed in the last WHO clinical pipeline report in
2019, EBL-1003 is one of only five candidate drugs that may hold
promise for efficacy against CRAB infections. Further evaluation in
patients will be required to underscore the clinical utility and
lasting success of new antibiotics in the treatment of CRAB
infections.
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